當(dāng)前位置: 首頁(yè) - 產(chǎn)品目錄 - 小分子抑制劑
Rapamycin (Sirolimus) 雷帕霉素
貨號(hào) | J9887 | 售價(jià)(元) | 680 |
規(guī)格 | 100mg | CAS號(hào) | 53123-88-9 |
- 產(chǎn)品簡(jiǎn)介
- 相關(guān)產(chǎn)品
產(chǎn)品信息
貨號(hào) |
名稱 |
規(guī)格 |
價(jià)格/元 |
J9883 |
Rapamycin (Sirolimus) 雷帕霉素 |
10mg |
248 |
J9885 |
Rapamycin (Sirolimus) 雷帕霉素 |
50mg |
480 |
J9887 |
Rapamycin (Sirolimus) 雷帕霉素 |
100mg |
680 |
J9889 |
Rapamycin (Sirolimus) 雷帕霉素 |
500mg |
2680 |
J9880 |
Rapamycin (Sirolimus) 雷帕霉素 |
1g |
3980 |
產(chǎn)品簡(jiǎn)介:
Rapamycin(雷帕霉素),又稱為Sirolimus和AY22989,是一種抗真菌和免疫抑制劑,特異性抑制mTOR蛋白(IC50約為0.1 nM)。Rapamycin與細(xì)胞內(nèi)受體FKBP-12結(jié)合形成復(fù)合物后,直接作用于mTOR中的FRB(FKBP-12-rapamycin binding)結(jié)構(gòu)域從而抑制蛋白活性。Rapamycin選擇性抑制IL-2誘導(dǎo)的p70 S6激酶磷酸化與功能活化,也可以促使4E-BP1/PHAS1去磷酸,從而加強(qiáng)與eIF4E的結(jié)合并使之失活。Rapamycin能夠阻斷蛋白合成,誘導(dǎo)細(xì)胞周期停滯在G1期。不同于FK506和其他免疫抑制劑,Rapamycin以非凋亡的方式阻斷活化T細(xì)胞增殖治療器官或骨髓移植中發(fā)生的排斥反應(yīng),比傳統(tǒng)治療方法副作用更少。
產(chǎn)品性質(zhì)
英文別名(English Synonym):AY 22989, Sirolimus, RAPA, NSC 226080, Rapamune?
化學(xué)名(Chemical Name):(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-
9, 10, 12, 13, 14, 21, 22, 23, 24, 25, 26, 27, 32, 33, 34, 34a-Hexadecahydro-9,27- dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylethyl]- 10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H- pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
靶點(diǎn)(Target):mTOR
CAS 號(hào)(CAS NO.):53123-88-9
分子式(Molecular Formula):C51H79NO13
分子量(Molecular Weight):914.17
外觀(Appearance):白色固體
純度(Purity):>99%
溶解性(Solubility):溶于DMSO(50 mg/ml),乙醇(50 mg/ml)
運(yùn)輸與保存方法
冰袋運(yùn)輸。粉末直接保存于-20 oC,有效期2年。溶于DMSO、乙醇。建議分裝后-20oC避光保存,避免反復(fù)凍存,至少可存放6個(gè)月。
相關(guān)產(chǎn)品:
貨號(hào) |
產(chǎn)品名稱 |
規(guī)格 |
價(jià)格/元 |
WU017 |
3-Methyladenine (3-MA) 3-甲基腺嘌呤 |
10mg |
238 |
J6280 |
MG 132 (MG-132) |
1mg |
479 |
WU034 |
Wortmannin (25mg/ml in DMSO) 渥曼青霉素 |
1mg |
390 |
WU077 |
Monensin, Sodium Salt 莫能霉素(鈉鹽) |
100mg |
460 |
使用濃度
【具體使用濃度請(qǐng)參考相關(guān)文獻(xiàn),并根據(jù)自身實(shí)驗(yàn)條件(如實(shí)驗(yàn)?zāi)康?,?xì)胞種類,培養(yǎng)特性等)進(jìn)行摸索和優(yōu)化?!?span>
相關(guān)實(shí)驗(yàn)(數(shù)據(jù)來(lái)自于公開發(fā)表的文獻(xiàn),僅供參考)
(一)細(xì)胞實(shí)驗(yàn)(體外研究)
Rapamycin顯著抑制T98G和U87-MG細(xì)胞活力,100 nM Rapamycin作用于對(duì)Rapamycin敏感的U87-MG和T98G細(xì)胞,通過(guò)抑制mTOR功能,而誘導(dǎo)細(xì)胞周期停在G1期。[3]
(二)動(dòng)物實(shí)驗(yàn)(體內(nèi)研究)
在體內(nèi)實(shí)驗(yàn)中,給小鼠腹腔注射4 mg/kg Rapamycin,Rapamycin有效抑制VEGF-A誘導(dǎo)的急性血管通透性,并完全抑制myrAkt1轉(zhuǎn)基因小鼠中血管形成。[6]
使用方法【源自文獻(xiàn),僅作參考】
文獻(xiàn)1,Iwamaru A et al. Silencing mammalian target of rapamycin signaling by small interfering RNA enhances rapamycin-induced autophagy in malignant glioma cells. Oncogene. 2007 Mar 22; 26(13):1840-51. PMID: 17001313
體外研究:
細(xì)胞類型(Cell type):Human malignant glioma U87-MG and A172 cells
藥物配制(Preparation):Rapamycin was dissolved in DMSO to make 1mM stock solution and stored at -20℃.
實(shí)驗(yàn)方法(Assay):Tumor cells were exposed to rapamycin (1, 10 or 100 nm) for 24 or 48 h. The cytotoxic effect of rapamycin was determined using a WST-1 cell proliferation assay.
文獻(xiàn)2,Caramés B et al. Autophagy activation by rapamycin reduces severity of experimental osteoarthritis. Ann Rheum Dis. 2012 Apr;71(4):575-81. PMID: 22084394
體內(nèi)研究:
動(dòng)物模型(Animal Model):Experimental osteoarthritis was induced in 2-month-old male C57Bl/6J mice
藥物配制(Preparation):Rapamycin was dissolved in DMSO at 25mg/ml and stored at -20℃. For injection, the stock solution was diluted in phosphate buffered saline (PBS).
注射劑量(Dosages):Mice received daily intraperitoneal injections of rapamycin at 1 mg/kg body weight/dose in a total injection volume of 0.3 ml for 10 weeks and control animals received the DMSO vehicle at 0.4% in a total injection volume of 0.3 ml.
給藥途徑(Administration):Intraperitoneal (i.p.) injection
文獻(xiàn)3,Eshleman JS et al. Inhibition of the Mammalian Target of Rapamycin Sensitizes U87 Xenografts to Fractionated Radiation Therapy. Cancer Res. 2002 Dec 15;62(24):7291-7. PMID: 12499272
體外研究:
細(xì)胞類型(Cell type):A172, U87, and U118 malignant glioma cell lines
藥物配制(Preparation):Rapamycin (NSC 226080) was dissolved in ethanol to yield a 5 mg/ml stock solution, which was stored at ?20°C.
實(shí)驗(yàn)方法(Assay):Tumor cells were incubated with 0 or 100 nM rapamycin at 37°C for 72 h and then processed in a MTS assay.
體內(nèi)研究:
動(dòng)物模型(Animal Model):8-10-week-old female athymic nude mice by s.c. injection of 2-5 million U87 cells
藥物配制(Preparation):For rapamycin injections, stock rapamycin was diluted first in sterile 10% PEG400/8% ethanol and then in an equal volume of sterile 10% Tween 80 for a final concentration of 20 μg rapamycin/100 μl. Rapamycin was delivered by i.p. injection, and the doses of rapamycin were calculated assuming that all mice weighed 20 g.
給藥途徑(Administration):Intraperitoneal (i.p.) injection
- 上一頁(yè): Rapamycin (Sirolimus) 雷帕霉素
- 下一頁(yè): Rapamycin (Sirolimus) 雷帕霉素